Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

• the present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
• MDS myelodysplastic syndrome
• MLL is a histone methyltransferase that methylates histone H3 on lysine 4 (H3K4) and functions in multiprotein complexes.
• HSCs hematopoietic stem cells
• B cells histone methyltransferase activity is dispensable for hematopoiesis ( Mishra et al., Cell Rep 2011. 7(4), 1239-47 ).
• Menin which is encoded by the Multiple Endocrine Neoplasia type 1 (MEN1 ) gene is expressed ubiquitously and is predominantly localized in the nucleus. It has been shown to interact with numerous proteins and is, therefore, involved in a variety of cellular processes. The best understood function of menin is its role as an oncogenic cofactor of MLL fusion proteins. Menin interacts with two motifs within the N-terminal fragment of MLL that is retained in all fusion proteins, MBM1 (menin-binding motif 1) and MBM2 ( Thiel et al., Bioessays 2012. 34, 771-80 ). Menin/MLL interaction leads to the formation of a new interaction surface for lens epithelium-derived growth factor (LEDGF).
• LEDGF lens epithelium-derived growth factor
• MLL directly binds to LEDGF
• menin is obligatory for the stable interaction between MLL and LEDGF and the gene specific chromatin recruitment of the MLL complex via the PWWP domain of LEDGF
• menin is strictly required for oncogenic transformation by MLL fusion proteins suggesting the menin/MLL interaction as an attractive therapeutic target.
• conditional deletion of Men1 prevents leukomogenesis in bone marrow progenitor cells ectopically expressing MLL fusions ( Chen et al., Proc Natl Acad Sci 2006. 103, 1018-23 ).
• menin/MLL fusion interaction by loss-of-function mutations abrogates the oncogenic properties of the MLL fusion proteins, blocks the development of leukemia in vivo and releases the differentiation block of MLL-transformed leukemic blasts.
• menin is required for the maintenance of HOX gene expression by MLL fusion proteins ( Yokoyama et al., Cell 2005. 123, 207-18 ).
• small molecule inhibitors of menin/MLL interaction have been developed suggesting druggability of this protein/protein interaction and have also demonstrated efficacy in preclinical models of AML ( Borkin et al., Cancer Cell 2015. 27, 589-602 ; Cierpicki and Grembecka, Future Med Chem 2014.
• the present invention concerns novel compounds of Formula (I) and the tautomers and the stereoisomeric forms thereof, wherein
• the present invention also relates to a pharmaceutical composition
• a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable salt, or a solvate thereof, and a pharmaceutically acceptable carrier or excipient.
• the invention relates to a compound of Formula (I), a pharmaceutically acceptable salt, or a solvate thereof, for use as a medicament, and to a compound of Formula (I), a pharmaceutically acceptable salt, or a solvate thereof, for use in the treatment or in the prevention of cancer, myelodysplastic syndrome (MDS) and diabetes.
• MDS myelodysplastic syndrome
• the invention relates to a compound of Formula (I), a pharmaceutically acceptable salt, or a solvate thereof, for use in the treatment or in the prevention of cancer.
• said cancer is selected from leukemias, myeloma or a solid tumor cancer (e.g. prostate cancer, lung cancer, breast cancer, pancreatic cancer, colon cancer, liver cancer, melanoma and glioblastoma, etc.).
• leukemias myeloma or a solid tumor cancer (e.g. prostate cancer, lung cancer, breast cancer, pancreatic cancer, colon cancer, liver cancer, melanoma and glioblastoma, etc.).
• the leukemias include acute leukemias, chronic leukemias, myeloid leukemias, myelogeneous leukemias, lymphoblastic leukemias, lymphocytic leukemias, Acute myelogeneous leukemias (AML), Chronic myelogenous leukemias (CML), Acute lymphoblastic leukemias (ALL), Chronic lymphocytic leukemias (CLL), T cell prolymphocytic leukemias (T-PLL), Large granular lymphocytic leukemia, Hairy cell leukemia (HCL), MLL-rearranged leukemias, MLL-PTD leukemias, MLL amplified leukemias, MLL-positive leukemias, leukemias exhibiting HOX / MEIS1 gene expression signatures etc.
• AML acute myelogeneous leukemias
• CML Chronic myelogenous leukemias
• ALL Acute lymphoblastic leukemia
• the invention also relates to the use of a compound of Formula (I), a pharmaceutically acceptable salt, or a solvate thereof, in combination with an additional pharmaceutical agent for use in the treatment or prevention of cancer, myelodysplastic syndrome (MDS) and diabetes.
• MDS myelodysplastic syndrome
• the invention relates to a process for preparing a pharmaceutical composition according to the invention, characterized in that a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable salt, or a solvate thereof.
• the invention also relates to a product comprising a compound of Formula (I), a pharmaceutically acceptable salt, or a solvate thereof, and an additional pharmaceutical agent, as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of cancer, myelodysplastic syndrome (MDS) and diabetes.
• a product comprising a compound of Formula (I), a pharmaceutically acceptable salt, or a solvate thereof, and an additional pharmaceutical agent, as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of cancer, myelodysplastic syndrome (MDS) and diabetes.
• MDS myelodysplastic syndrome
• the invention relates to a method of treating or preventing a cell proliferative disease in a warm-blooded animal which comprises administering to the said animal an effective amount of a compound of Formula (I), a pharmaceutically acceptable salt, or a solvate thereof, as defined herein, or a pharmaceutical composition or combination as defined herein.
• 'halo' or 'halogen' as used herein represents fluoro, chloro, bromo and iodo.
• 'C x-y ' refers to the number of carbon atoms in a given group.
• a C 1-6 alkyl group contains from 1 to 6 carbon atoms
• a C 3-6 cycloalkyl group contains from 3 to 6 carbon atoms, and so on.
• 'C 1-4 alkyl' as used herein as a group or part of a group represents a straight or branched chain saturated hydrocarbon radical having from 1 to 4 carbon atoms, such as methyl, ethyl, n -propyl, isopropyl, n -butyl, s -butyl, t -butyl and the like.
• 'C 2-4 alkyl' as used herein as a group or part of a group represents a straight or branched chain saturated hydrocarbon radical having from 2 to 4 carbon atoms, such as ethyl, n -propyl, isopropyl, n -butyl, s -butyl, t -butyl and the like.
• 'C 1-6 alkyl' as used herein as a group or part of a group represents a straight or branched chain saturated hydrocarbon radical having from 1 to 6 carbon atoms such as the groups defined for C 1-4 alkyl and n -pentyl, n -hexyl, 2-methylbutyl and the like.
• 'C 3-5 cycloalkyl' as used herein as a group or part of a group defines a saturated, cyclic hydrocarbon radical having from 3 to 5 carbon atoms, such as cyclopropyl, cyclobutyl and cyclopentyl.
• 'C 3-6 cycloalkyl' as used herein as a group or part of a group defines a saturated, cyclic hydrocarbon radical having from 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
• ⁇ spiro bicyclic' systems are cyclic systems wherein two cycles are joined at a single atom.
• Examples of 7- to 10-membered saturated spirocarbobicyclic systems include, but are not limited to and the like.
• 'substituted' is used in the present invention, it is meant, unless otherwise indicated or clear from the context, to indicate that one or more hydrogens, in particular from 1 to 4 hydrogens, more in particular from 1 to 3 hydrogens, preferably 1 or 2 hydrogens, more preferably 1 hydrogen, on the atom or radical indicated in the expression using 'substituted' are replaced with a selection from the indicated group, provided that the normal valency is not exceeded, and that the substitution results in a chemically stable compound, i.e. a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture.
• substituents When two or more substituents are present on a moiety they may, where possible and unless otherwise indicated or clear from the context, replace hydrogens on the same atom or they may replace hydrogen atoms on different atoms in the moiety.
• a substituent on a heterocyclyl group may replace any hydrogen atom on a ring carbon atom or on a ring heteroatom (e.g. a hydrogen on a nitrogen atom may be replaced by a substituent).
• a 'non-aromatic group' embraces unsaturated ring systems without aromatic character, partially saturated and fully saturated carbocyclic and heterocyclic ring systems.
• the term ⁇ fully saturated' refers to rings where there are no multiple bonds between ring atoms.
• a 'non-aromatic heterocyclyl' is a non-aromatic monocyclic or bicyclic system, unless otherwise specified, having for example, 3 to 12 ring members, more usually 5 to 10 ring members.
• monocyclic groups are groups containing 4 to 7 ring members, more usually, 5 or 6 ring members.
• Examples of bicyclic groups are those containing 8 to 12, more usually 9 or 10 ring members.
• Non-limiting examples of monocyclic heterocyclyl systems containing at least one heteroatom selected from nitrogen, oxygen or sulfur (N, O, S) include, but are not limited to 4- to 7-membered heterocyclyl systems such as azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyranyl, dihydropyranyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl.
• Non-limiting examples of bicyclic heterocyclyl systems containing at least one heteroatom selected from nitrogen, oxygen or sulfur (N, O, S) include, but are not limited to octahydro-1H-indolyl, indolinyl, Unless otherwise specified, each can be bound to the remainder of the molecule of Formula (I) through any available ring carbon atom (C-linked) or nitrogen atom (N-linked), and may optionally be substituted, where possible, on carbon and/or nitrogen atoms according to the embodiments.
• Examples of a C-linked 4- to 7-membered non-aromatic heterocyclyl containing at least one nitrogen atom include, but are not limited to, azetidinyl, pyrrolidinyl and piperidinyl, bound to the rest of the molecule through an available carbon atom.
• Lines (such as '---') drawn into ring systems indicate that the bond may be attached to any of the suitable ring atoms.
• Het 1 , Het 2 and Het 3 may be attached to the remainder of the molecule of Formula (I) through any available ring carbon or nitrogen atom as appropriate, if not otherwise specified.
• each definition is independent.
• subject refers to an animal, preferably a mammal (e.g. cat, dog, primate or human), more preferably a human, who is or has been the object of treatment, observation or experiment.
• a mammal e.g. cat, dog, primate or human
• terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medicinal doctor or other clinician, which includes alleviation or reversal of the symptoms of the disease or disorder being treated.
• composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
• treatment is intended to refer to all processes wherein there may be a slowing, interrupting, arresting or stopping of the progression of a disease, but does not necessarily indicate a total elimination of all symptoms.
• compound(s) of the (present) invention or “compound(s) according to the (present) invention” as used herein, is meant to include the compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof.
• the invention includes all stereoisomers of the compounds of the invention either as a pure stereoisomer or as a mixture of two or more stereoisomers.
• Enantiomers are stereoisomers that are non-superimposable mirror images of each other.
• a 1:1 mixture of a pair of enantiomers is a racemate or racemic mixture.
• Atropisomers are stereoisomers which have a particular spatial configuration, resulting from a restricted rotation about a single bond, due to large steric hindrance. All atropisomeric forms of the compounds of Formula (I) are intended to be included within the scope of the present invention.
• Diastereomers are stereoisomers that are not enantiomers, i.e. they are not related as mirror images. If a compound contains a double bond, the substituents may be in the E or the Z configuration.
• Substituents on bivalent cyclic saturated or partially saturated radicals may have either the cis- or trans-configuration; for example if a compound contains a disubstituted cycloalkyl group, the substituents may be in the cis or trans configuration.
• the invention includes enantiomers, atropisomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof, whenever chemically possible.
• the absolute configuration is specified according to the Cahn-Ingold-Prelog system.
• the configuration at an asymmetric atom is specified by either R or S .
• Resolved stereoisomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light.
• resolved enantiomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light.
• stereoisomer is substantially free, i.e. associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, in particular less than 2% and most preferably less than 1%, of the other stereoisomers.
• a compound of Formula (I) is for instance specified as ( R )
• a compound of Formula (I) is for instance specified as E
• this means that the compound is substantially free of the Z isomer
• a compound of Formula (I) is for instance specified as cis, this means that the compound is substantially free of the trans isomer.
• salts include acid addition salts and base addition salts.
• Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form with one or more equivalents of an appropriate base or acid, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration).
• Salts may also be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.
• the pharmaceutically acceptable salts as mentioned hereinabove or hereinafter are meant to comprise the therapeutically active non-toxic acid and base salt forms which the compounds of Formula (I) and solvates thereof, are able to form.
• Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e.
• salt forms can be converted by treatment with an appropriate base into the free base form.
• the compounds of Formula (I) and solvates thereof containing an acidic proton may also be converted into their non-toxic metal or amine salt forms by treatment with appropriate organic and inorganic bases.
• Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, cesium, magnesium, calcium salts and the like, salts with organic bases, e.g.
• primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline; the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
• the salt form can be converted by treatment with acid into the free acid form.
• solvate comprises the solvent addition forms as well as the salts thereof, which the compounds of Formula (I) are able to form.
• solvent addition forms are e.g. hydrates, alcoholates and the like.
• the compounds of the invention as prepared in the processes described below may be synthesized in the form of mixtures of enantiomers, in particular racemic mixtures of enantiomers, that can be separated from one another following art-known resolution procedures.
• a manner of separating the enantiomeric forms of the compounds of Formula (I), and pharmaceutically acceptable salts, and solvates thereof involves liquid chromatography using a chiral stationary phase.
• Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
• the present invention also embraces isotopically-labeled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (or the most abundant one found in nature).
• isotopes and isotopic mixtures of any particular atom or element as specified herein are contemplated within the scope of the compounds of the invention, either naturally occurring or synthetically produced, either with natural abundance or in an isotopically enriched form.
• Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and iodine, such as 2 H, 3 H , 11 C, 13 C, 14 C , 13 N, 15 O, 17 O, 18 O, 32 P, 33 P, 35 S, 18 F, 36 Cl, 122 I, 123 I, 125 I, 131 I, 75 Br, 76 Br, 77 Br and 82 Br.
• the radioactive isotope is selected from the group of 2 H, 3 H, 11 C and 18 F. More preferably, the radioactive isotope is 2 H.
• deuterated compounds are intended to be included within the scope of the present invention.
• Certain isotopically-labeled compounds of the present invention may be useful for example in substrate tissue distribution assays. Tritiated ( 3 H) and carbon-l4 ( 14 C) isotopes are useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
• R 2 is selected from hydrogen or deuterium, in particular deuterium.
• L 2 can be >C( 2 H) 2 .
• Positron emitting isotopes such as 15 O, 13 N, 11 C and 18 F are useful for positron emission tomography (PET) studies.
• PET imaging in cancer finds utility in helping locate and identify tumours, stage the disease and determine suitable treatment.
• Human cancer cells overexpress many receptors or proteins that are potential disease-specific molecular targets.
• Radiolabelled tracers that bind with high affinity and specificity to such receptors or proteins on tumour cells have great potential for diagnostic imaging and targeted radionuclide therapy ( Charron, Carlie L. et al. Tetrahedron Lett. 2016, 57(37), 4119-4127 ).
• target-specific PET radiotracers may be used as biomarkers to examine and evaluate pathology, by for example, measuring target expression and treatment response ( Austin R. et al. Cancer Letters (2016), doi: 10.1016/j.canlet.2016.05.008 ).
• the present invention relates in particular to compounds of Formula (I) as defined herein, and the tautomers and the stereoisomeric forms thereof, wherein
• the present invention relates in particular to compounds of Formula (I) as defined herein, and the tautomers and the stereoisomeric forms thereof, wherein
• the present invention relates in particular to compounds of Formula (I) as defined herein, and the tautomers and the stereoisomeric forms thereof, wherein
• the present invention relates in particular to compounds of Formula (I) as defined herein, and the tautomers and the stereoisomeric forms thereof, wherein
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein L 1 is a 8- to 9- membered fused heterocycle of Formula (a-3)
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein L 1 is a 8- to 9- membered fused heterocycle of Formula (a-1), (a-2), (a-3), (a-4), (a-5), (a-6), (a-7), (a-8), (a-9), (a-10) or (a-11)
• Another embodiment of the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments wherein one or more of the following restrictions apply:
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein at least one of m, n, q and p is different from 0.
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein m is 1.
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein n is 1.
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein p is 1 or 2.
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein q is 1.
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R 1 is CF 3
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R 1 is CF 3 , and wherein R 2 is hydrogen.
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is phenyl optionally substituted according to any of the other embodiments.
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein --L 2 -R 3 is (a).
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein --L 2 -R 3 is (b).
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein --L 2 -R 3 is (c).
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein --L 2 -R 3 is (d).
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein --L 2 -R 3 is (a); R 3 is Het 1 or Het 2 .
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein --L 2 -R 3 is (a); R 3 is Het 1 .
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het 2 is piperidinyl or tetrahydropyranyl, each of which are optionally substituted with one, two, or three substituents as described in the other embodiments.
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het 2 is monocyclic heterocyclyl optionally substituted with one, two, or three substituents as described in the other embodiments.
• the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
• Particular compounds of Formula (I) are: including the stereoisomeric forms, the pharmaceutically acceptable salts thereof, in particular the hydrochloride salts thereof, and the solvates thereof.
• Particular compounds of Formula (I) are compounds 70, 71B, 36, 87 and 102, including the stereoisomeric forms, the pharmaceutically acceptable salts thereof, in particular the hydrochloride salts thereof, and the solvates thereof.
• Particular compounds of Formula (I) are compounds 70, 71B, 36, 87 and 102.
• the compound of Formula (I) is selected from the group consisting of any of the exemplified compounds, and the free bases, the pharmaceutically acceptable addition salts, and the solvates thereof.
• references to Formula (I) also include all other sub-groups and examples thereof as defined herein.
• compounds of the present invention may also be prepared by analogous reaction protocols as described in the general schemes below, combined with standard synthetic processes commonly used by those skilled in the art of organic chemistry.
• reaction work-up refers to the series of manipulations required to isolate and purify the product(s) of a chemical reaction such as for example quenching, column chromatography, extraction).
• microwave heating may be used instead of conventional heating to shorten the overall reaction time.
• the compounds of Formula (I) may be synthesized in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures.
• the racemic compounds of Formula (I) containing a basic nitrogen atom may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali.
• An alternative manner of separating the enantiomeric forms of the compounds of Formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
• Suitable amino-protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (Boc), benzyloxycarbonyl (CBz) and 9-fluorenylmethyleneoxycarbonyl (Fmoc).
• step 1 can be performed in the presence of a suitable catalyst such as platinium oxide, in a suitable solvent such as for example ethanol at a suitable temperature such as for example 60°C;
• a suitable catalyst such as platinium oxide
• a suitable solvent such as for example ethanol
• a suitable temperature such as for example 60°C;
• L x is a bond or -CHR 5a - wherein R 5a is H or C 1-4 alkyl. All other variables in Scheme 8 are defined according to the scope of the present invention.
• the compounds of the present invention block the interaction of menin with MLL proteins and oncogenic MLL fusion proteins. Therefore the compounds according to the present invention and the pharmaceutical compositions comprising such compounds may be useful for the treatment or prevention, in particular treatment, of diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
• diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
• a solid tumor cancer e.g. prostate cancer, lung cancer, breast cancer, pancreatic cancer, colon cancer, liver cancer, melanoma and glioblastoma, etc.
• the leukemias include acute leukemias, chronic leukemias, myeloid leukemias, myelogeneous leukemias, lymphoblastic leukemias, lymphocytic leukemias, Acute myelogeneous leukemias (AML), Chronic myelogenous leukemias (CML), Acute lymphoblastic leukemias (ALL), Chronic lymphocytic leukemias (CLL), T cell prolymphocytic leukemias (T-PLL), Large granular lymphocytic leukemia, Hairy cell leukemia (HCL), MLL-rearranged leukemias, MLL-PTD leukemias, MLL amplified leukemias, MLL-positive leukemias, leukemias exphibiting HOX / MEIS1 gene expression signatures etc.
• AML acute myelogeneous leukemias
• CML Chronic myelogenous leukemias
• ALL Acute lymphoblastic leuk
• the invention relates to compounds of Formula (I), the tautomers and the stereoisomeric forms thereof, and the pharmaceutically acceptable salts, and the solvates thereof, for use as a medicament.
• the invention also relates to the use of a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable salt, or a solvate thereof, or a pharmaceutical composition according to the invention, for the manufacture of a medicament.
• the present invention also relates to a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable salt, or a solvate thereof, or a pharmaceutical composition according to the invention, for use in the treatment, prevention, amelioration, control or reduction of the risk of disorders associated with the interaction of menin with MLL proteins and oncogenic MLL fusion proteins in a mammal, including a human, the treatment or prevention of which is affected or facilitated by blocking the interaction of menin with MLL proteins and oncogenic MLL fusion proteins.
• the present invention relates to the use of a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable salt, or a solvate thereof, or a pharmaceutical composition according to the invention, for the manufacture of a medicament for treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with the interaction of menin with MLL proteins and oncogenic MLL fusion proteins in a mammal, including a human, the treatment or prevention of which is affected or facilitated by blocking the interaction of menin with MLL proteins and oncogenic MLL fusion proteins.
• the invention also relates to a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable salt, or a solvate thereof, for use in the treatment or prevention of any one of the diseases mentioned hereinbefore.
• the invention also relates to a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable salt, or a solvate thereof, for use in treating or preventing any one of the diseases mentioned hereinbefore.
• the invention also relates to the use of a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable salt, or a solvate thereof, for the manufacture of a medicament for the treatment or prevention of any one of the disease conditions mentioned hereinbefore.
• the compounds of the present invention can be administered to mammals, preferably humans, for the treatment or prevention of any one of the diseases mentioned hereinbefore.
• Said method comprises the administration, i.e. the systemic or topical administration, preferably oral administration, of a therapeutically effective amount of a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable salt, or a solvate thereof, to warm-blooded animals, including humans.
• administration i.e. the systemic or topical administration, preferably oral administration, of a therapeutically effective amount of a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable salt, or a solvate thereof, to warm-blooded animals, including humans.
• the invention also relates to a method for the treatment or prevention of any one of the diseases mentioned hereinbefore comprising administering a therapeutically effective amount of compound according to the invention to a patient in need thereof.
• a therapeutically effective amount of the compounds of the present invention is the amount sufficient to have therapeutic activity and that this amount varies inter alias, depending on the type of disease, the concentration of the compound in the therapeutic formulation, and the condition of the patient.
• the amount of a compound of the present invention to be administered as a therapeutic agent for treating the disorders referred to herein will be determined on a case by case by an attending physician.
• An effective therapeutic daily amount would be from about 0.005 mg/kg to 100 mg/kg, in particular 0.005 mg/kg to 50 mg/kg, in particular 0.01 mg/kg to 50 mg/kg body weight, more in particular from 0.01 mg/kg to 25 mg/kg body weight, preferably from about 0.01 mg/kg to about 15 mg/kg, more preferably from about 0.01 mg/kg to about 10 mg/kg, even more preferably from about 0.01 mg/kg to about 1 mg/kg, most preferably from about 0.05 mg/kg to about 1 mg/kg body weight.
• a particular effective therapeutic daily amount might be 1 mg/kg body weight, 2 mg/kg body weight, 4 mg/kg body weigth, or 8 mg/kg body weight.
• the amount of a compound according to the present invention, also referred to herein as the active ingredient, which is required to achieve a therapeutically effect may vary on case-by-case basis, for example with the particular compound, the route of administration, the age and condition of the recipient, and the particular disorder or disease being treated.
• a method of treatment may also include administering the active ingredient on a regimen of between one and four intakes per day.
• the compounds according to the invention are preferably formulated prior to administration.
• suitable pharmaceutical formulations are prepared by known procedures using well known and readily available ingredients.
• compositions for preventing or treating the disorders referred to herein comprising a therapeutically effective amount of a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable salt, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent.
• the present invention further provides a pharmaceutical composition comprising a compound according to the present invention, together with a pharmaceutically acceptable carrier or diluent.
• a pharmaceutically acceptable carrier or diluent must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
• compositions of this invention may be prepared by any methods well known in the art of pharmacy, for example, using methods such as those described in Gennaro et al. Remington's Pharmaceutical Sciences (18th ed., Mack Publishing Company, 1990 , see especially Part 8 : Pharmaceutical preparations and their Manufacture).
• a therapeutically effective amount of the particular compound, in base form or salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration.
• compositions are desirably in unitary dosage form suitable, preferably, for systemic administration such as oral, percutaneous or parenteral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like.
• systemic administration such as oral, percutaneous or parenteral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like.
• topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like.
• any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions: or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets.
• tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
• the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
• injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
• injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
• the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
• These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on or as an ointment.
• Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
• dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
• the present compounds can be used for systemic administration such as oral, percutaneous or parenteral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like.
• the compounds are preferably orally administered.
• the exact dosage and frequency of administration depends on the particular compound of Formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art.
• said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.
• the compounds of the present invention may be administered alone or in combination with one or more additional therapeutic agents.
• Combination therapy includes administration of a single pharmaceutical dosage formulation which contains a compound according to the present invention and one or more additional therapeutic agents, as well as administration of the compound according to the present invention and each additional therapeutic agent in its own separate pharmaceutical dosage formulation.
• a compound according to the present invention and a therapeutic agent may be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent may be administered in separate oral dosage formulations.
• an embodiment of the present invention relates to a product containing as first active ingredient a compound according to the invention and as further active ingredient one or more anticancer agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of patients suffering from cancer.
• the one or more other medicinal agents and the compound according to the present invention may be administered simultaneously (e.g. in separate or unitary compositions) or sequentially in either order. In the latter case, the two or more compounds will be administered within a period and in an amount and manner that is sufficient to ensure that an advantageous or synergistic effect is achieved.
• the preferred method and order of administration and the respective dosage amounts and regimes for each component of the combination will depend on the particular other medicinal agent and compound of the present invention being administered, their route of administration, the particular condition, in particular tumour, being treated and the particular host being treated. The optimum method and order of administration and the dosage amounts and regime can be readily determined by those skilled in the art using conventional methods and in view of the information set out herein.
• the weight ratio of the compound according to the present invention and the one or more other anticancer agent(s) when given as a combination may be determined by the person skilled in the art. Said ratio and the exact dosage and frequency of administration depends on the particular compound according to the invention and the other anticancer agent(s) used, the particular condition being treated, the severity of the condition being treated, the age, weight, gender, diet, time of administration and general physical condition of the particular patient, the mode of administration as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. A particular weight ratio for the present compound of Formula (I) and another anticancer agent may range from 1/10 to 10/1, more in particular from 1/5 to 5/1, even more in particular from 1/3 to 3/1.
• 'AcN' or 'ACN' means acetonitrile
• ⁇ DCM' means dichloromethane
• 'DIEA' or 'DIPEA' means N,N-diisopropylethylamine
• 'h' means hours(s)
• ⁇ min' means minute(s)
• ⁇ DMF' means dimethylformamide
• 'DSC' means differential scanning calorimetry
• 'Et 3 N' or 'TEA' means triethylamine
• 'EtOAc' or 'EA' means ethyl acetate
• 'Et 2 O' means diethyl ether
• 'EtOH' means ethanol
• ⁇ FA' means formic acid
• ⁇ HOBt' or ⁇ HOBT' means 1-hydroxy-1H-benzotriazole
• 'HPLC' means High-performance Liquid Chromatography
• 'prep-HPLC' means preparative HPLC
• compounds synthesised using the protocols as indicated may exist as a solvate e.g. hydrate, and/or contain residual solvent or minor impurities.
• Compounds isolated as a salt form may be integer stoichiometric i.e. mono- or di-salts, or of intermediate stoichiometry.
• the stereochemical configuration for centres in some compounds may be designated " R " or " S " when the mixture(s) was separated; for some compounds, the stereochemical configuration at indicated centres has been designated as "* R " (first eluted from the column in case the column conditions are described in the synthesis protocol and when only one stereocentre present) or " ⁇ S " (second eluted from the column in case the column conditions are described in the synthesis protocol and when only one stereocentre present) when the absolute stereochemistry is undetermined (even if the bonds are drawn stereospecifically) although the compound itself has been isolated as a single stereoisomer and is enantiomerically pure.
• enantiomerically pure means that the product contains at least 80% by weight of one enantiomer and 20% by weight or less of the other enantiomer. Preferably the product contains at least 90% by weight of one enantiomer and 10% by weight or less of the other enantiomer. In the most preferred embodiment the term “enantiomerically pure” means that the composition contains at least 99% by weight of one enantiomer and 1% or less of the other enantiomer.
• the stereochemical configuration at indicated centres has also been designated " ⁇ R " or " ⁇ S " when a single stereocentre is present in combination with 2 adjacent chiral bridging atoms in the fused hetereocycle L 1 , and when the absolute stereochemistry of the single stereocentre is undetermined (even if the bonds are drawn stereospecifically) but enantiomerically pure.
• the stereochemical configuration of the two stereocentres are indicated by ⁇ (e.g. ⁇ R or ⁇ S). Even if the bonds are drawn stereospecifically, the ⁇ R and ⁇ S indicate that the configuration of the first stereocentre is only known relatively to the other stereocentre in the fused heterocycle L 1 , although the compound itself has been isolated as a single stereoisomer.
• tert-butyl octahydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (3 g, 13.3 mmol), cis relative mixture ( CAS[848410-13-9 ]) prepared as described in Bioorganic & Medicinal Chemistry Letters, 2005,15(4), 977-982 ; 4-chloro-6-(2,2,2-trifluoroethyl)thieno[2,3- d ]pyrimidine ( CAS[1628317-85-0 ]) (3.5 g, 13.9 mmol) prepared as described in Journal of Medicinal Chemistry (2016), 59(3), 892-913 ; DIEA (6.9 mL, 39.8 mmol) in iPrOH (60 mL) were heated at 90°C overnight.
• HBTU 101 mg; 0.3 mmol
• Boc-L-Proline CAS [15761-39-4 ]
• DIEA 0.2 mL; 1.3 mmol
• the solution was stirred at 10°C for 30 min then, intermediate 8 (100 mg; 0.3 mmol) was added and the reaction mixture was stirred at rt for 15h.
• the solution was poured into cooled water, a 10% solution of K 2 CO 3 was added and EtOAc.
• the first eluted product was freeze dried with ACN/water 20/80 yielding 240 mg (24%) of compound 71A .
• the second eluted compound was freeze-dried with ACN/water 20/80 yielding 200 mg (21%) of compound 71B .
• the compound 71 was freeze dried with ACN/water 20/80 yielding 20 mg (2%) of compound 71.
• 1-methyl-2-imidazolecarboxaldehyde (137,4 mg, 1.25 mmol) was added to a solution of intermediate 3 (250 mg, 0.61 mmol) in dry DCM (10 mL). The mixture was stirred at room temperature for 5h. Then NaBH(OAc) 3 (260 mg; 1.23 mmol) was added portionwise and the mixture was stirred at rt for 72h. The reaction mixture was poured into ice water and the organic layer was separated, the aqueous layer was extracted with DCM twice. The organic layers were combined, washed with brine then dried over MgSO 4 , evaporated.
• the fractions containing product were collected and evaporated to dryness.
• the residue (65 mg) was purified by reverse phase (Stationary phase: 10 ⁇ m 30*150 mm, Mobile phase gradient from 60% NH 4 CO 3 (0.2%), 40% ACN to 0% NH 4 CO 3 (0.2%), 100% ACN).
• the fractions containing product were collected and evaporated to dryness yielding 32 mg of product.
• the product was freeze dried with Acetonitrile/water 20/80 to give 26 mg (19%) of compound 26.
• the compound 27 was submitted to chiral SFC (Stationary phase: CHIRACEL ® OJ-H l 5 ⁇ m 250 ⁇ 20mm , Mobile phase: 85% CO 2 , 15% MeOH(0.30% iPrNH 2 )). The fractions containing products were collected, evaporated to dryness yielding 114 mg (20%) of compound 27A and 128 mg (22%) of compound 27B.
• Compound 27A was dissolved in ACN and converted into hydrochloric saltby treatment with HCl. The precipitate was filtered and dried providing 80 mg of compound 27C.
• Benzyl bromide (CAS : [100-39-0 ]) (95 ⁇ L, 0.8 mmol) and then potassium carbonate (205 mg, 1.5 mmol) were successively added to a solution of intermediate 31 (235 mg, 0.7 mmol) in ACN (12 mL) and the mixture was stirred at rt overnight. The mixture was poured into ice water and EtOAc was added. The organic layer was separated, washed with brine, dried over MgSO 4 , filtered and evaporated till dryness.
• the residue (700 mg) was purified by reverse phase (Stationary phase: irregular 5 ⁇ m 150*25 mm, mobile phase gradient: 70% NH 4 HCO 3 (0.05%), 30% ACN to 40% NH 4 HCO 3 (0.05%), 60% ACN).
• the fractions containing product were collected and evaporated to dryness yielding 95 mg (yield 25%) compound 34.
• the residue (145 mg) was purified by chromatography over silica gel (Stationary phase: irregular bare silica 12 g, Mobile phase gradient: 0.1% NH 4 OH, 97% DCM, 3% MeOH to 0.1% NH 4 OH, 95% DCM, 5% MeOH). The fractions containing product were collected and evaporated to dryness.
• the residue (71 mg) was purified by chromatography over silica gel (Stationary phase: irregular bare silica 12 g, Mobile phase gradient: 0.1% NH 4 OH, 97% DCM, 3% MeOH to 0.1% NH 4 OH, 95% DCM, 5% MeOH). The fractions containing product were collected and evaporated to dryness. The compound was freeze-dried with ACN/water (20/80) yielding 30 mg of compound 72.
• the fractions containing product were collected and evaporated to dryness.
• the residue was purified by reverse phase (Stationary phase: C18 10 ⁇ m 30* 150mm, Mobile phase: Gradient from 75% NH 4 HCO 3 0.2% , 25% ACN to 35% NH 4 HCO 3 0.2% , 65% ACN).
• the fractions containing product were collected and evaporated to dryness to give 11 mg of compound which was taken up with Et 2 O and evaporated till dryness to give 10 mg of compound 75 .
• acetyl chloride (CAS [75-36-5 ]) (25 ⁇ E; 0.3 mmol) was added to a solution of compound 70B (100 mg; 0.2 mmol) and DIEA (79 ⁇ L; 0.5 mmol) in DCM (5 mL). The reaction mixture was stirred at rt for 4h. The reaction was poured into ice water, basified with a 10% aqueous solution of K 2 CO 3 and DCM was added. The organic layer was separated, dried over MgSO 4 , filtered and evaporated till dryness.
• the reaction mixture was stirred at 0°C for 30 min and allowed to slowly rise to rt for 24 h.
• the solution was poured into ice water, EtOAc was added and filtered through a pad of Celite ® .
• the organic layer was separated, dried over MgSO 4 , filtered and evaporated till dryness.
• the residue (226 mg) was purified by chromatography over silica gel (Stationary phase: irregular bare silica 12 g, Mobile phase: 0.1% NH 4 OH, 97% DCM, 3% MeOH).
• the compounds were prepared using an analogous method as described for the preparation of compound 77, 77A and 77B starting from the intermediate 8 and methylmagnesium bromide in solution 3M in Et 2 O.
• NMR experiments were carried out using a Bruker Avance 500 spectrometer equipped with a Bruker 5mm BBFO probe head with z gradients and operating at 500 MHz for the proton and 125 MHz for carbon, or using a Bruker Avance DRX 400 spectrometer using internal deuterium lock and equipped with reverse double-resonance ( 1 H, 13 C, SEI) probe head with z gradients and operating at 400 MHz for the proton and 100MHz for carbon. Chemical shifts ( ⁇ ) are reported in parts per million (ppm). J values are expressed in Hz.
• HPLC High Performance Liquid Chromatography
• MS Mass Spectrometer
• SQL Single Quadrupole Detector
• RT room temperature
• BEH bridged ethylsiloxane/silica hybrid
• HSS High Strength Silica
• DAD Diode Array Detector
• melting points were determined with a DSC1 (Mettler-Toledo). Melting points were measured with a temperature gradient of 10 °C/minute. Maximum temperature was 300 °C. Values are peak values.”
• the SFC measurement was performed using an Analytical Supercritical fluid chromatography (SFC) system composed by a binary pump for delivering carbon dioxide (CO 2 ) and modifier, an autosampler, a column oven, a diode array detector equipped with a high-pressure flow cell standing up to 400 bars. If configured with a Mass Spectrometer (MS) the flow from the column was brought to the (MS). It is within the knowledge of the skilled person to set the tune parameters (e.g. scanning range, dwell time%) in order to obtain ions allowing the identification of the compound's nominal monoisotopic molecular weight (MW). Data acquisition was performed with appropriate software. Table 2a.
• SFC Analytical Supercritical fluid chromatography
• Optical Rotation is measured with a polarimeter 341 Perkin Elmer.
• the polarized light is passed through a sample with a path length of 1 decimeter and a sample concentration of 0.2 to 0.4 gram per 100 milliliters. 2 to 4 mg of the product in vial are weight, then dissolved with 1 to 1.2 ml of spectroscopy solvent (DMF for example).
• DMF spectroscopy solvent
• the cell is filled with the solution and put into the polarimeter at a temperature of 20 °C.
• the OR is read with 0.004° of precision.
• black 384-well microtiter plate was added 50 nL 160X test compound in DMSO and 4 ⁇ L 2X menin in assay buffer (40 mM Tris ⁇ HCl, pH 7.5, 50 mM NaCl, 1 mM DTT and 0.001% Tween 20). After incubation of test compound and menin for 10 min at ambient temperature, 4 ⁇ L 2X FITC-MBM1 peptide (FITC- ⁇ -alanine-SARWRFPARPGT-NH 2 ) in assay buffer was added, the microtiter plate centrifuged at 1000 rpm for 1 min and the assay mixtures incubated for 15 min at ambient temperature.
• assay buffer 40 mM Tris ⁇ HCl, pH 7.5, 50 mM NaCl, 1 mM DTT and 0.001% Tween 20.
• the relative amount of menin ⁇ FITC-MBM1 complex present in an assay mixture is determined by measuring the fluorescence polarization (FP) of the FITC label with a BMG Pherastar plate reader (ex. 485 nm/em. 520 nm) at ambient temperature.
• the final concentrations of reagents in the binding assay are 100 nM menin, 5 nM FITC-MBM1 peptide and 0.625% DMSO in assay buffer.
• Dose-response titrations of test compounds are conducted using an 11 point, three-fold serial dilution scheme, starting at 31 ⁇ M.
• % inhibition HC ⁇ LC ⁇ FP compound ⁇ LC / HC ⁇ LC ) ⁇ 100
• LC and HC are the FP values of the assay in the presence or absence of a saturating concentration of a compound that competes with FITC-MBM1 for binding to menin
• FP compound is the measured FP value in the presence of the test compound.
• HC and LC FP values represent an average of at least 16 replicates per plate.
• IC 50 is the concentration of compound that yields 50% inhibition of signal and h is the Hill coefficient.
• the anti-proliferative effect of menin/MLL protein/protein interaction inhibitor test compounds was assessed in human leukemia cell lines.
• the cell lines MV-4-11 and MOLM14 harbor MLL translocations and express the MLL fusion proteins MLL-AF4 and MLL-AF9, respectively, as well as the wildtype protein from the second allele. Therefore, the MLL rearranged cell lines MV-4-11 and MOLM14 exhibit stem cell-like HOXA / MEIS1 gene expression signatures.
• K562 and KG1 were used as a control cell lines containing two MLL wildtype alleles in order to exclude compounds that display general cytotoxic effects.
• MV-4-11 and MOLM14 were cultured in RPMI-1640 (Sigma Aldrich) supplemented with 10% fetal bovine serum (HyClone), 2 mM L-glutamine (Sigma Aldrich) and 50 ⁇ g/ml gentamycin (Gibco).
• K562 were propagated in RPMI-1640 (Sigma Aldrich) supplemented with 20% fetal bovine serum (HyClone), 2 mM L-glutamine (Sigma Aldrich) and 50 ⁇ g/ml gentamycin (Gibco).
• KG1 were cultured in Iscove's MDM (Gibco) supplemented with 20% fetal bovine serum (HyClone), 2 mM L-glutamine (Sigma Aldrich) and 50 ⁇ g/ml gentamycin (Gibco). Cells were kept at 0.3 - 2.5 million cells per ml during culturing and passage numbers did not exceed 25.
• MV-4-11, 300 MOLM14, 750 K562 or 1,300 KG1 cells were seeded in 200 ⁇ l media per well in 96-well round bottom, ultra-low attachment plates (Costar, catalogue number 7007). Cell seeding numbers were chosen based on growth curves to ensure linear growth throughout the experiment. Test compounds were added at different concentrations and the DMSO content was normalized to 0.3%. Cells were incubated for 8d at 37°C and 5% CO 2 . Spheroid like growth was monitored in real-time by live-cell imaging (IncuCyteZOOM, Essenbio, 4x objective) acquiring one image every four hours for 8d. Confluence (%) as a measure of spheroid size was determined using an integrated analysis tool.
• the degree of fluorescence resonance energy transfer (the HTRF value) is expressed as the ratio of the fluorescence emission intensities of the FITC and terbium fluorophores ( F em 520 nm/ F em 490 nm).
• the final concentrations of reagents in the binding assay are 100 pM terbium chelate-labeled menin, 75 nM FITC-MBM1 peptide and 0.5% DMSO in assay buffer. Dose-response titrations of test compounds are conducted using an 11 point, three-fold serial dilution scheme, starting at 31 ⁇ M.
• % inhibition HC ⁇ LC ⁇ HTRF compound ⁇ LC / HC ⁇ LC ) ⁇ 100
• LC and HC are the HTRF values of the assay in the presence or absence of a saturating concentration of a compound that competes with FITC-MBM1 for binding to menin
• HTRF compound is the measured HTRF value in the presence of the test compound.
• HC and LC HTRF values represent an average of at least 16 replicates per plate.
• IC 50 is the concentration of compound that yields 50% inhibition of signal and h is the Hill coefficient.
• Menin (a.a. 1-610-6xhis tag) was labeled with terbium cryptate as follows. 2mg of Menin was buffer exchanged into 1x phosphate buffered saline. 16uM Menin was incubated with 4-fold molar excess NHS-terbium cryptate (Cisbio Bioassays, Bedford, MA) for 2 hours at room temperature. The labeled protein was purified away from free label by running the reaction over a Superdex 200 Increase 10/300 GL column at 0.75ml/min. Peak fractions were collected, aliquoted and frozen at -80 °C.
• MENIN Protein Sequence SEQ ID NO: 1: Table 4. Biological data in the Menin fluorescence polarization (FP) assay (1), Menin/MLL homogenous time-resolved fluorescence (HTRF) assay (3) and proliferation assay (2). Co. No. means compound number. The values in table 4 are averaged values over all measurements. Co. No.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Diabetes (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Hematology (AREA)
• Engineering & Computer Science (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Obesity (AREA)
• Oncology (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Peptides Or Proteins (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (4)

Publications (3)

Family

ID=59901513

Family Applications (1)

Country Status (13)

Families Citing this family (29)

Citations (3)

Family Cites Families (36)

• 2017
  • 2017-09-13 CA CA3033020A patent/CA3033020A1/en active Pending
  • 2017-09-13 ES ES17768750T patent/ES2966316T3/es active Active
  • 2017-09-13 JP JP2019535973A patent/JP7033141B2/ja active Active
  • 2017-09-13 US US16/331,579 patent/US10611778B2/en active Active
  • 2017-09-13 TW TW106131464A patent/TWI753016B/zh not_active IP Right Cessation
  • 2017-09-13 CN CN201780056197.2A patent/CN109715634B/zh active Active
  • 2017-09-13 MA MA046228A patent/MA46228A/fr unknown
  • 2017-09-13 KR KR1020197007938A patent/KR102493364B1/ko active Active
  • 2017-09-13 AU AU2017326485A patent/AU2017326485B2/en not_active Ceased
  • 2017-09-13 MX MX2019002959A patent/MX389598B/es unknown
  • 2017-09-13 WO PCT/EP2017/073001 patent/WO2018050684A1/en not_active Ceased
  • 2017-09-13 EP EP17768750.6A patent/EP3512858B1/en active Active
• 2019
  • 2019-03-07 IL IL265231A patent/IL265231B/en active IP Right Grant
• 2020
  • 2020-02-13 US US16/789,707 patent/US10975100B2/en active Active

Patent Citations (3)

Also Published As

Similar Documents

Legal Events